Tag: Investigational New Drug Application (IND)
Nestlé Acquires Aimmune, Partners with Enterome to Develop Food Allergy and...
Nestlé, the consumer products powerhouse, is expanding its pharmaceutical portfolio with massive investments.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
FDA Green Lights Phase 2 Trials of PVX108, a Novel Peptide-Driven...
Phase 2 study of candidate from Aravax will commence in the US and Australia.
Aquestive’s Sublingual Epinephrine Achieves Therapeutic Blood Concentrations Following Administration
Company presented top level Phase 1 results at #AAAAI2022 meeting.
Study Finds Microneedle Delivery Successful in Test of Peanut Allergy Immunotherapy
Study finds five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch.
Microneedle Dermal Stamp to Treat Peanut Allergy Takes Another Step Forward
Moonlight Therapeutics received FDA guidance for first in-human clinical trial of MOON101.
FDA Accepts Investigational New Drug Application for Novel Peanut Allergy Therapy
The company, which is already in phase 2 clinical trials with a treatment for celiac disease, has announced the FDA has accepted their Investigational New Drug (IND) application for evaluation of CNP-201, A treatment for peanut allergy. that reduces the need for strict peanut avoidance and reduces the potentially fatal health risks associated with peanut allergy.
Aquestive Charts Ambitious Path Forward for Sublingual Emergency Epinephrine
Company updates the public on status of their candidate drug administered under the tongue.
Peanut Allergy Vaccine Takes Another Step with Biomarker Study
Study will help establish the starting dose of its vaccine candidate for a subsequent in-human phase I study.
Toothpaste Therapy for Food Allergies Takes Another Step Forward
FDA accepts IND application by Intrommune Therapeutics.
